|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
iCyt unveils 405nm-excited fluorochrome conjugated antibodies for flow cytometry
|
|
ICyt
: 13 April, 2011 (New Product) |
|
|
iCyt Mission Technology (iCyt), a wholly-owned subsidiary of Sony Corporation of America, is introducing its new line of 405nm-excited fluorochrome conjugated antibodies for flow cytometry. |
|
|
The new Brilliant Violet 421 products are part of the first commercial release of a novel, polymer-based fluorophore technology.
'This exciting new class of fluorescent probes will make significant contributions to the future of flow cytometry, by bringing new power and utility to the violet (405nm) laser,' said Gary Durack, Chief Executive Officer of iCyt. 'The new Brilliant Violet fluors offer dramatic improvements in brightness and signal-to-noise ratio over the current choices for the violet laser.'
In addition to being an order of magnitude brighter than traditional violet excited fluorochromes, this new dye offers greater sensitivity for resolving weakly expressed antigens, and requires less compensation for spectral overlap. Their compatibility with other popular fluorochromes and fluorescent protein combinations offers versatility that will further expand researchers' options for multi-colour panels.
The initial iCyt portfolio of anti-mouse and anti-human conjugates have been optimised for use with iCyt's Eclipse analyser and upcoming Synergy benchtop sorter, but are compatible with all major commercial flow cytometers equipped with a 405nm laser.
The new BV421 line will include an extensive antibody selection that combines consistent bright staining that is effective for surface and intracellular antigens, with simple, ready-to-use, low volume test size. The new probes are fixation stable and compatible with standard staining buffers.
iCyt intends to continually expand its new line of BV reagents, which complement its already broad portfolio of mouse and human monoclonal antibodies tailored for use in cell biology, immunology, cancer research, and stem cell research.
'iCyt and Sony are committed to leading the way in bringing innovative, new instrument and reagent technology combinations to market, that maximise performance and value for our customers,' added Durack.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
